DE69936134D1 - Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren - Google Patents

Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren

Info

Publication number
DE69936134D1
DE69936134D1 DE69936134T DE69936134T DE69936134D1 DE 69936134 D1 DE69936134 D1 DE 69936134D1 DE 69936134 T DE69936134 T DE 69936134T DE 69936134 T DE69936134 T DE 69936134T DE 69936134 D1 DE69936134 D1 DE 69936134D1
Authority
DE
Germany
Prior art keywords
recombinant
viruses
production
adenovires
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69936134T
Other languages
English (en)
Inventor
Tong-Chuan He
Bert Vogelstein
Kenneth W Kinzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Application granted granted Critical
Publication of DE69936134D1 publication Critical patent/DE69936134D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/38—Vector systems having a special element relevant for transcription being a stuffer
DE69936134T 1998-02-27 1999-02-25 Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren Expired - Lifetime DE69936134D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/031,917 US5922576A (en) 1998-02-27 1998-02-27 Simplified system for generating recombinant adenoviruses
PCT/US1999/004062 WO1999043843A1 (en) 1998-02-27 1999-02-25 A simplified system for generating recombinant adenoviruses

Publications (1)

Publication Number Publication Date
DE69936134D1 true DE69936134D1 (de) 2007-07-05

Family

ID=21862097

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69936134T Expired - Lifetime DE69936134D1 (de) 1998-02-27 1999-02-25 Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren

Country Status (7)

Country Link
US (1) US5922576A (de)
EP (1) EP1056881B1 (de)
AT (1) ATE362989T1 (de)
AU (1) AU747847B2 (de)
CA (1) CA2322066A1 (de)
DE (1) DE69936134D1 (de)
WO (1) WO1999043843A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820868A (en) 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
US20020193580A1 (en) * 1995-12-15 2002-12-19 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US20060088938A1 (en) * 1995-12-15 2006-04-27 Mitchell Lloyd G Methods and compositions for use in spliceosome mediated RNA trans-splicing in plants
US20030027250A1 (en) * 1995-12-15 2003-02-06 Mitchell Lloyd G. Methods and compositions for use in spliceosome mediated RNA trans-splicing
US6420629B1 (en) * 1996-09-09 2002-07-16 B.C. Research Inc. Process of increasing plant growth and yield and modifying cellulose production in plants
ATE348155T1 (de) 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
JP4812914B2 (ja) 1997-06-23 2011-11-09 ユニバーシティ オブ サスカチュワン ウシアデノウイルスタイプ３ゲノム
ATE386138T1 (de) * 1998-03-28 2008-03-15 Univ Utah Res Found Zielgerichtete antisense-bibliotheken
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CN1342206A (zh) * 1998-08-28 2002-03-27 杜克大学 在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
US6303362B1 (en) 1998-11-19 2001-10-16 The Board Of Trustees Of The Leland Stanford Junior University Adenoviral vector and methods for making and using the same
WO2001021761A2 (es) * 1999-09-17 2001-03-29 Tgt Laboratories, S.A. De C.V. Vectores adenovirales recombinantes y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar y cicatrices hipertroficas
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
US6867022B1 (en) * 2000-01-21 2005-03-15 Regents Of The University Of Michigan Replication deficient adenovirus vectors and methods of making and using them
WO2001059071A2 (en) * 2000-02-09 2001-08-16 Genvec, Inc. Methods of preparing and using a viral vector library
US6830920B2 (en) * 2000-03-08 2004-12-14 University Of Iowa Research Foundation Rapid generation of recombinant adenoviral vectors
JP2003534805A (ja) * 2000-05-31 2003-11-25 ユニバーシティ オブ サスカチュワン 変化した親和性を有する改変ウシアデノウイルス
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
EP1317560A4 (de) * 2000-09-08 2005-10-05 Gen Hospital Corp Sich selbst neuordnende dna vektoren(18.03.02)
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
JP2004513638A (ja) * 2000-11-10 2004-05-13 アストラゼネカ・アクチエボラーグ ベクター
GB0027501D0 (en) * 2000-11-10 2000-12-27 Astrazeneca Ab Vector
MXPA00011713A (es) * 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
US20040126774A1 (en) * 2001-01-08 2004-07-01 Mitchell Lioyd G. Correction of factor VIII genetic defects using spliceosome mediated RNA trans splicing
US20020177229A1 (en) * 2001-01-19 2002-11-28 Ivo Piest Swap/counter selection: a rapid cloning method
US6838285B2 (en) 2001-09-18 2005-01-04 Becton Dickinson Site specific recombinase based method for producing adenoviral vectors
JP4488290B2 (ja) * 2002-01-24 2010-06-23 ザ・スクリップス・リサーチ・インスティテュート 効率的ターゲティングのためのファイバーシャフト変異
US7399753B2 (en) * 2002-02-25 2008-07-15 Virxsys Corporation Trans-splicing mediated photodynamic therapy
JP2005536231A (ja) * 2002-05-08 2005-12-02 イントロン，インコーポレーテッド アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型ｒｎａトランススプライシングの使用
EP3170890A1 (de) 2002-08-21 2017-05-24 Revivicor, Inc. Schweine ohne expression von funktionaler alpha-1,3-galactosyltransferase
GB2409681B (en) * 2002-09-27 2007-03-28 Powderject Res Ltd Nucleic acid constructs for gene expression
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2005001133A2 (en) * 2003-06-03 2005-01-06 Collateral Therapeutics, Inc. Compositions and methods for high throughput construction and functional analysis of expression libraries
WO2004108755A2 (en) * 2003-06-10 2004-12-16 University Of Saskatchewan Chimeric adenovirus capsid proteins
US20070213288A1 (en) * 2003-07-17 2007-09-13 University Of South Florida Adenoviral Vector Capable of Infecting Tumor Cells and Eliminating the Function of STAT3
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US20070003520A1 (en) * 2003-11-17 2007-01-04 Brown Susanne M Mutant viruses
US7897146B2 (en) * 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
US8053232B2 (en) * 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
US7968334B2 (en) * 2004-01-23 2011-06-28 Virxsys Corporation Expression of apoAI and variants thereof using spliceosome mediated RNA trans-splicing
US20060177933A1 (en) * 2004-01-23 2006-08-10 Madaiah Puttaraju Expression of apoA-1 and variants thereof using spliceosome mediated RNA trans-splicing
US8603824B2 (en) 2004-07-26 2013-12-10 Pfenex, Inc. Process for improved protein expression by strain engineering
EP1771571A2 (de) * 2004-07-30 2007-04-11 Targeted Genetics Corporation Impfungsmethode basierend auf rekombinant aav
US20060094110A1 (en) * 2004-07-30 2006-05-04 Mcgarrity Gerard J Use of spliceosome mediated RNA trans-splicing for immunotherapy
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules
DE102004047492B4 (de) * 2004-09-23 2006-07-20 Jost-Werke Gmbh & Co. Kg Verfahren zum Übertragen von elektrischer, pneumatischer oder hydraulischer Energie sowie ein Energieübertragungssystem
US7871795B2 (en) 2004-10-08 2011-01-18 Virxsys Corporation Targeted trans-splicing of highly abundant transcripts for in vivo production of recombinant proteins
WO2006083331A2 (en) * 2004-10-08 2006-08-10 Intronn, Inc Use of rna trans-splicing for antibody gene transfer and antibody polypeptide production
CA2586107A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. A novel method for the production and purification of adenoviral vectors
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
EP2551282A3 (de) 2005-03-23 2013-02-13 Genmab A/S Antikörper gegen CD38 zur Behandling von multiplem Myelom
WO2006127956A2 (en) * 2005-05-23 2006-11-30 Vaxin, Inc. Rapid production of adenovirus-free recombinant adenovirus vectors
EP1924686A4 (de) 2005-08-09 2009-11-11 Revivicor Inc Ctla4-ig exprimierende transgene huftiere und deren verwendung
KR100723009B1 (ko) * 2005-11-30 2007-05-29 한국원자력연구원 인간 ｐ３１ 유전자를 함유하는 악성 종양 치료용 약학적조성물
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
DK1971862T3 (da) 2006-04-11 2011-02-14 Arena Pharm Inc Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
EP1900749A1 (de) 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nukleinsäuren zur Expression von Polynukleotiden in Säuger-Krebszellen
EP2415783B1 (de) 2006-10-16 2016-12-14 Genelux Corporation Modifizierte Impfstoffvirusstämme zur Verwendung in einem Diagnose- und Therapieverfahren
DE102006060799A1 (de) 2006-12-21 2008-06-26 RUHR-UNIVERSITäT BOCHUM RSV F-Protein und seine Verwendung
EP2615172A1 (de) 2007-04-27 2013-07-17 Pfenex Inc. Schnellscreeningverfahren für Bakterienwirte zur Identifizierung bestimmter Stämme mit verbessertem Ertrag und/oder verbesserter Qualität bei der Expression heterologer Proteine
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2171071B1 (de) * 2007-06-15 2015-08-05 Genelux Corporation Für ein natriumabhängiges transporterprotein codierende vacciniavirus-vektoren zur bildlichen darstellung und/oder behandlung von tumoren
EP2612868B1 (de) 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunsuppressive Polypeptide und Nucleinsäuren
EP2108960A1 (de) * 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Verfahren zur Verwendung eines A G Protein-gekoppelten Rezeptors zur Identifikation von Peptid YY (PYY) Sekretagoga und nützliche Verbindungen zur Behandlung von durch (PYY) Sekretagoga modulierten Zuständen und nützliche Verbindungen zur Behandlung von Zuständen durch PYY
WO2012142529A2 (en) 2011-04-15 2012-10-18 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US20130280170A1 (en) 2012-04-20 2013-10-24 Aladar A. Szalay Imaging methods for oncolytic virus therapy
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
CN113088530A (zh) * 2020-01-08 2021-07-09 怡道生物科技(苏州)有限公司 一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
CN111549065B (zh) * 2020-04-01 2023-11-24 广州医科大学附属第一医院（广州呼吸中心） 应用腺病毒转导制备能够表达人源apn转基因非人动物的方法，及所得动物的应用
WO2024011250A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2727689A1 (fr) * 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
WO1998032860A1 (en) * 1997-01-28 1998-07-30 Baxter International Inc. Methods for highly efficient generation of adenoviral vectors

Also Published As

Publication number Publication date
AU747847B2 (en) 2002-05-23
ATE362989T1 (de) 2007-06-15
EP1056881B1 (de) 2007-05-23
CA2322066A1 (en) 1999-09-02
EP1056881A1 (de) 2000-12-06
AU2787599A (en) 1999-09-15
WO1999043843A1 (en) 1999-09-02
US5922576A (en) 1999-07-13

Similar Documents

Publication Publication Date Title
DE69936134D1 (de) Ein vereinfachtes system zur herstelliung von rekombinanten adenoviren
McGrory et al. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5
CN105518138B (zh) CRISPR-Cas9特异性敲除猪GFRA1基因的方法及用于特异性靶向GFRA1基因的sgRNA
FI111384B (fi) Menetelmä modifioidun selkärankaispoxviruksen molekylaariseksi kloonaamiseksi, modifioitu virus, sen DNA ja sen käyttö
NZ269019A (en) Method of inducing transduction with retroviral assistance
NZ316389A (en) Retroviral packaging plasmid and methods of use thereof
WO2002014495A3 (en) Enhanced homologous recombination mediated by lambda recombination proteins
CA2321964A1 (en) Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant virus
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
DE69534902D1 (de) Rekombinanter viraler DNS Vektor zur Transfektion tierischer Zellen
AU7075691A (en) Vaccines
DE69634043D1 (de) Zirkuläres dna molekül mit einem abhängigen replikationsursprung, seine herstellungsverfahren und seine verwendung in der gentherapie
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
ATE278024T1 (de) Methode zur herstellung von rekombinanten zellen
HUP9901790A2 (hu) Kationos viroszómák mint genetikai anyag bevitelére alkalmas rendszerek
ATE526818T1 (de) Gentechnisch hergestellte wasserlinse
CN108795986A (zh) 一种a型血友病慢病毒载体、慢病毒及其制备方法和应用
TR200001046T2 (tr) Homolog rekombinasyonda pozitif-negatif seçimi.
HUP9904329A2 (hu) Herpeszvirus saimiri mint vírusvektor
DK0843731T3 (da) Adenovirusvektorer til genterapi
JP6667432B2 (ja) 遺伝子移入促進因子プロトランスズジン（Ｐｒｏｔｒａｎｓｄｕｚｉｎ）Ｂ
BRPI0414670A (pt) método para preparar uma célula, célula, métodos para fornecer uma célula e para gerar uma batelada de adenovìrus recombinante, molécula recombinante, conjunto de pelo menos duas moléculas de ácido nucleico, e, sistema de empacotamento
DK0880594T3 (da) Retroviral vektor og dens anvendelse i genterapi
Riedl et al. Rescue of Recombinant Adenoviruses by CRISPR/Cas-Mediated in vivo Terminal Resolution
CN1252274C (zh) 用于将外源基因导入气道上皮细胞的重组仙台病毒载体

Legal Events

Date Code Title Description
8332 No legal effect for de